Literature DB >> 21621856

Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier.

Takafumi Hosokawa1, Hideto Nakajima, Yoshimitsu Doi, Masakazu Sugino, Fumiharu Kimura, Toshiaki Hanafusa, Toshiyuki Takahashi.   

Abstract

Matrix metalloproteinase-9 (MMP-9) plays an important role in some neuroinflammatory diseases through the blood-brain barrier (BBB) disruption. To investigate the pathogenicity of MMP-9 in neuromyelitis optica (NMO), serum and CSF MMP-9 concentrations were measured in 13 NMO and 15 multiple sclerosis (MS) patients and 14 healthy controls, and correlated with clinical and laboratorial parameters. Serum MMP-9 concentrations were significantly higher in NMO than MS and controls, and correlated with EDSS score, CSF/serum albumin ratio, and CSF IL-8 concentrations. Our results indicate that MMP-9, promoted by elevated IL-8 activation, plays a crucial role in the pathogenesis of NMO through the BBB disruption.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621856     DOI: 10.1016/j.jneuroim.2011.04.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

Review 1.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

2.  Astrocytic TYMP and VEGFA drive blood-brain barrier opening in inflammatory central nervous system lesions.

Authors:  Candice Chapouly; Azeb Tadesse Argaw; Sam Horng; Kamilah Castro; Jingya Zhang; Linnea Asp; Hannah Loo; Benjamin M Laitman; John N Mariani; Rebecca Straus Farber; Elena Zaslavsky; German Nudelman; Cedric S Raine; Gareth R John
Journal:  Brain       Date:  2015-03-23       Impact factor: 13.501

3.  Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis.

Authors:  Fabian D Liechti; Denis Grandgirard; David Leppert; Stephen L Leib
Journal:  Infect Immun       Date:  2014-02-03       Impact factor: 3.441

4.  Cytokines and matrix metalloproteinases in the cerebrospinal fluid of patients with acute transverse myelitis: an outcome analysis.

Authors:  Puneet Dixit; Ravindra Kumar Garg; Hardeep Singh Malhotra; Amita Jain; Rajesh Verma; Praveen Kumar Sharma; Neeraj Kumar
Journal:  Inflamm Res       Date:  2015-11-25       Impact factor: 4.575

Review 5.  Development, maintenance and disruption of the blood-brain barrier.

Authors:  Birgit Obermeier; Richard Daneman; Richard M Ransohoff
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

Review 6.  Anti-NR2A/B Antibodies and Other Major Molecular Mechanisms in the Pathogenesis of Cognitive Dysfunction in Systemic Lupus Erythematosus.

Authors:  Sen Hee Tay; Anselm Mak
Journal:  Int J Mol Sci       Date:  2015-05-06       Impact factor: 5.923

7.  Interferon-β1b increases Th2 response in neuromyelitis optica.

Authors:  Hideto Nakajima; Takafumi Hosokawa; Yoshimitu Doi; Toshiyuki Ikemoto; Shimon Ishida; Fumiharu Kimura; Toshiaki Hanafusa
Journal:  Int J Mol Sci       Date:  2012-09-25       Impact factor: 5.923

Review 8.  Hypersensitivity Responses in the Central Nervous System.

Authors:  Reza Khorooshi; Nasrin Asgari; Marlene Thorsen Mørch; Carsten Tue Berg; Trevor Owens
Journal:  Front Immunol       Date:  2015-10-07       Impact factor: 7.561

Review 9.  The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.

Authors:  Michalina Jasiak-Zatonska; Alicja Kalinowska-Lyszczarz; Slawomir Michalak; Wojciech Kozubski
Journal:  Int J Mol Sci       Date:  2016-03-02       Impact factor: 5.923

10.  Risk of macular degeneration affected by polymorphisms in Matrix metalloproteinase-2: A case-control study in Chinese Han population.

Authors:  Jie Cheng; Xiaolin Hao; Zhongchen Zhang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.